Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $18.00.

OMER has been the topic of several analyst reports. HC Wainwright started coverage on shares of Omeros in a report on Tuesday, June 10th. They set a "buy" rating and a $9.00 price target on the stock. Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Friday, May 16th.

Hedge Funds Weigh In On Omeros

Several large investors have recently made changes to their positions in the company. Truvestments Capital LLC lifted its position in Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Omeros in the fourth quarter valued at $46,000. Picton Mahoney Asset Management lifted its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Price Performance

NASDAQ OMER traded up $0.01 during trading on Monday, reaching $3.22. 568,278 shares of the company's stock were exchanged, compared to its average volume of 692,140. The business has a 50 day moving average price of $4.87 and a 200-day moving average price of $7.50. The stock has a market capitalization of $188.66 million, a P/E ratio of -1.22 and a beta of 2.20. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). On average, analysts forecast that Omeros will post -3.09 earnings per share for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.